Sincalide
Clinical data
Other names1-De(5-oxo-L-proline)-2-de-L-glutamine-
5-L-methioninecaerulein, 3-[[2-[[2-[[2-[[2-[[2-[(2-amino-3-carboxy-propanoyl)
amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4-
methylsulfanyl-butanoyl]amino]acetyl]amino]-3-
(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanyl-
butanoyl]amino]-3-[(1-carbamoyl-2-phenyl-ethyl)
carbamoyl]propanoic acid
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
  • UK: Available on a named-patient basis
  • US: ℞-only
Identifiers
  • α-aspartyl-O-sulfotyrosylmethionylglycyltryptophylmethionyl-α-aspartylphenylalaninamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.042.384
Chemical and physical data
FormulaC49H62N10O16S3
Molar mass1143.27 g·mol−1
3D model (JSmol)
  • CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)N
  • InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1 ☒N
  • Key:IZTQOLKUZKXIRV-YRVFCXMDSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Sincalide (INN) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin, and also known as CCK-8.

Common adverse effects following administration include abdominal discomfort and nausea. These effects are more pronounced following rapid infusion.

Clinical Use

Indications

Sincalide may be used to stimulate gallbladder contraction, as may be assessed by contrast agent cholecystography or ultrasonography, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals.[1] It can also be used to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology. In some instances it is used to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and-extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.[2]

References

  1. ↑ Ziessman HA (September 2019). "Sincalide: A Review of Clinical Utility, Proper Infusion Methodology, and Alternative Cholecystogogues". Journal of Nuclear Medicine Technology. 47 (3): 210–212. doi:10.2967/jnmt.119.226019. PMID 31019045. S2CID 131775567.
  2. ↑ Kinevac Package Insert



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.